Právní předpis byl sestaven k datu 05.04.2017.
Zobrazené znění právního předpisu je účinné od 20.09.2014 do 05.04.2017.
47
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x. x č. 46/2008 Xx. x. x. a nahrazuje xxxxxxx Xxxxxxxxxxxx zahraničních xxxx č. 98/2013 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 11. xxxxxxxxx 2013 xxxx generální ředitelkou XXXXXX xxxxxxxx schválení xxxxxx znění Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx.1)
X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx a xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx změny Xxxxxxx X Xxxxxx xxxxxxxxxx.
Xxxx znění Přílohy X xxxxxxxxx x xxxxxxxx v souladu x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2014 a xxxxx xxxx vstoupilo x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx přestalo xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx pod č. 98/2013 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x xxxx xxxxxxx xx českého jazyka xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXXXXXX ÚMLUVA XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2014
XXXXXX XXXXXXXXXX XXXXX X METOD DOPINGU XXX ROK 2014
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2014
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx M1, X2 a X3.
|
XXXXX X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ) |
ZAKÁZANÉ XXXXX
X0. XXXXXXXXXXX LÁTKY
Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx a xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx klinickém xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.
X1. ANABOLICKÉ XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3b,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); bolasteron; xxxxxxxx; xxxxxxx (androsta-1,4-dien-3,17-dion); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); fluoxymesteron; xxxxxxxxxx; furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; stanozolol; stenbolon; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (androst-4-en-3,17-dion), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx a xxxxxx metabolity x xxxxxxx, ale xx x xxxxxxxx pouze xx xx:
|
5α-xxxxxxxxx-3α,17α-xxxx |
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
|
5α-xxxxxxxxx-3α,17β-xxxx |
xxx-xxxxxxxxxxxxxxxxxx |
|
5α-xxxxxxxxx-3β,17α-xxxx |
xxxxxxxxxxxxxx |
|
5α-xxxxxxxxx-3β,17β-xxxx |
xxxxxxxxxxxxxx |
|
xxxxxxx-4-xx-3α,17α-xxxx |
3α-xxxxxxx-5αxxxxxxxxx-17-xx |
|
xxxxxxx-4-xx-3α,17β-xxxx |
3β-xxxxxxx-5αxxxxxxxxx-17-xx |
|
xxxxxxx-5-xx-3β,17α-xxxx |
7α-xxxxxxx-XXXX |
|
xxxxxxx-5-xx-3α,17α-xxxx |
7β-xxxxxxx-XXXX |
|
xxxxxxx-5-xx-3α,17β-xxxX |
7-xxxx-XXXX |
|
xxxxxxx-5-xx-3β,17α-xxxx |
19-xxxxxxxxxxxxxx |
|
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) |
19-xxxxxxxxxxxxxxxxx |
Xxx xxxxx xxxxxxx xxxx sekce:
* "exogenní" xx xxxxxxxx x xxxxx, kterou tělo xxxxxxxx přirozeně xxxxxxxxxxx.
** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
X2. XXXXXXXXX HORMONY, XXXXXXX XXXXXXX A PŘÍBUZNÉ XXXXX
Xxxxxxxxxxx xxxxx a xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx xxxx zakázány:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (LH) x xxxxxx uvolňující xxxxxxx u mužů;
3. Xxxxxxxxxxxxxx x jejich xxxxxxxxxx xxxxxxx;
4. Xxxxxxx xxxxxx (GH) x xxxx xxxxxxxxxx xxxxxxx x xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1).
Kromě xxxx xxxx xxxxxxxx xxxxxxxxxxx růstové xxxxxxx:
Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx typy svalových xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky.
S3. XXXX2- XXXXXXXX
Xxxxxxx beta-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx isomerů (např. x- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx salbutamolu (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 hodin) x salmeterolu, xxxxx xxxx podány x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx formoterolu v xxxx v koncentraci xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx bude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky xxxxx xxx xxxx uvedené xxxxxxx.
X4. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, xxxxxxxxx, letrozol, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Raloxifen, xxxxxxxxx, xxxxxxxxx, ale xx x omezením pouze xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX v xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX A OSTATNÍ XXXXXXXXX LÁTKY
Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, nitrožilní podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx, xxxxxxx (xxxx. xxxxxxxxx) x xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (tj. xxxxxxxxxx, salbutamol, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Podání nebo xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx červených krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx oběhového xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx xxxxx na xx. Xxxxxxxxxxxx kyslíkem zakázána xxxx.
3. Jakákoliv forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je následující:
1. Xxxxxxxxx, nebo xxxxx x xxxxxx, xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx ne x xxxxxxxx pouze xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx vyšetřovacích metod.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxx;
2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
|
XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI |
Kromě xxxxxxxxx X0 xx X5 x M1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx všech xxxxxx případných xxxxxxxxx xxxxxxx (xxxx. d- x x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (karfedon)/, xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, krotetamid, mefenorex, xxxxxxxxxxx, metamfetamin (d-), xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, prolintan.
Stimulancium, xxxxx není xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx (xxxxxxxxx)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, hydroxyamfetamin (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx xxxxxxx (xxxx. mefedron, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, metylfenidát, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), níketamid, xxxxxxxxxxx, oktopamin, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), trimetazidin, xxxxxxxxxxxxx x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxx je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
*** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx v 1 xx moči.
**** Xxxxxxx xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. nosní, oční xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, pokud xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx.
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, oxykodon, xxxxxxxxx, xxxxxxxxxx, petidin.
S8. KANABINOIDY
Přírodní (xxxx. hašiš, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x kanabimimetika (xxxx. "Xxxxx", XXX018, XXX073 x XX-210) jsou xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Všechny glukokortikosteroidy xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
|
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX |
X1. ALKOHOL
Alkohol (xxxxxx) xx zakázaný xxxxx Xxx Soutěži x xxxxxxxxxxxxx sportech. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx je xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0.10 x/x.
• Xxxxxxxxxxxx sport (XXX)
• Karate (XXX)
• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
• Xxxxxxxxxxx (XX)
• Xxxxxxxxxxx xxxxx (XXX)
• Vodní motorismus (XXX)
X2. BETA-BLOKÁTORY
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
• Xxxxxxxxxxxx xxxxx (XXX)
• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• Xxxx (IGF)
• Lukostřelba (XX) (zakázané xxxx Xxxx xxxxxx)
• Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, a xxxxxxxxx X-xxxxx a "big xxx"
• Střelba (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
• Xxxxx (XXX)
Xxxx-xxxxxxxxx zahrnují následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s omezením xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 47/2014 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.9.2014.
Xxxxxx předpis x. 47/2014 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.
Znění xxxxxxxxxxxx xxxxxxxx norem jiných xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx právního xxxxxxxx.